Cardiovascular Outcome of Cancer Patients: The "GMEDICO Cohort"
ConditionCardiovascular Prognosis
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAssistance Publique Hopitaux De Marseille
About this trial
The Mediterranean Group of Cardio-Oncology (GMEDICO) brings together French cardiologists and oncologists who have developed a protocol for the monitoring and cardio-oncological management of patients treated for cancer.
This unique organization makes it possible to envisage the creation of a large cohort from which the incidence and predictive factors of cardiovascular toxicity can be determined.
Primary objective: to determine the cardiovascular prognosis of patients treated for cancer and followed up in cardio-oncology.
Secondary objectives
* To determine the clinical, biological and imaging factors associated with cardiovascular events under cancer treatment, in order to define a risk score including clinical, biological (biomarker) and imaging data. * To create a biological source for testing other biomarkers and conducting genome-wide association studies and genetic factors associated with cardiovascular events under cancer treatment.
Eligibility criteria
Qualifiers
All adults referred for specialist cardio-oncology consultations before the initiation of a cancer treatment according to pre-established indications will be eligible.
Disqualifiers
Failure to provide information that makes it impossible to complete a consultation form or refuse to sign the consent.
Minor or major patient under guardianship
Pregnant or breastfeeding woman
Trial design
Treatments tested in this trial
- blood samples
Treatment groups
530 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov